ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built.

ALX will be initiating a new trial combining evorpacept with a HER2 antibody (zanidatamab) in breast cancer (Fig. 1). The trial just started, so data is not expected for a while.